Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezetimibe/rosuvastatin calcium - Merck Sharp & Dohme

Next Previous
Drug Profile

Ezetimibe/rosuvastatin calcium - Merck Sharp & Dohme

Alternative Names: Ezetimibe 10mg/Rosuvastatin Ca 20mg; HCP 1306; HCP-1903; ID1801; MK 0653H; Rosuzet

Latest Information Update: 07 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Hanmi Pharmaceutical; Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia
  • Registered Hyperlipoproteinaemia type IIa
  • Phase III Hypertension

Most Recent Events

  • 03 Jan 2025 Hanmi Pharmaceutical completes a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT06518122)
  • 24 Jul 2024 Hanmi Pharmaceutical plans a phase I drug-drug interaction trial in Healthy volunteers in South Korea (NCT06518122)
  • 04 Dec 2019 IlDong Pharmaceutical plans a phase I pharmacodynamics/pharmacokinetic interaction and safety study in Healthy volunteers (ID-VARE-101; NCT04185090)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top